Comparative Pharmacology
Head-to-head clinical analysis: CIN QUIN versus QUALAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIN QUIN versus QUALAQUIN.
CIN-QUIN vs QUALAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)